Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy
|
|
- Ethelbert Henderson
- 6 years ago
- Views:
Transcription
1 Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Faculty Disclosures Dr. Holle has provided content expertise on patient education materials for Innocrin Pharmaceuticals Inc. investigational drugs Lisa M. Holle, PharmD, BCOP, FHOPA Associate Clinical Professor Learning Objectives At the conclusion of this presentation, participants should be able to: Describe common dispensing and administration challenges with oral anticancer medications Identify potentially significant drug drug interactions with oral anticancer medications Describe proper handling and disposal of oral anticancer medications Oral Cytotoxic Agents 6 Mercaptopurine 1953 Etoposide 1986 Methotrexate 1953 Altretamine 1990 Busulfan 1954 Capecitabine 1998 Chlorambucil 1957 Cyclophosphamide 1999 Melphalan 1964 Temozolomide 1999 Thioguanine 1966 Topetecan 1999 Procarbazine 1969 Fludarabine 2008 Lomustine 1976 Trifluridine/tipiracil 2015 Estramustine 1981 Hormonal Agents Tamoxifen 1977 Flutamide 1989 Anastrozole 1995 Bicalutamide 1995 Nilutamide 1996 Letrozole 1997 Exemestane 2005 Abiraterone 2011 Enzalutamide 2012 Targeted/Biologic Agents Thalidomide 1998 Nilotinib 2007 Regorafenib 2012 Bexarotene 1999 Everolimus 2009 Vismodegib 2012 Imatinib 2001 Pazopanib 2009 Afatanib 2013 Erlotinib 2004 Crizotinib 2011 Dabrafenib 2013 Tretinoin 2004 Ruxolitinib 2011 Trametinib 2012 Lenalidomide 2005 Vandetanib 2011 Pomalidomide 2013 Sorafenib 2005 Vemurafenib 2011 Ibrutinib 2013 Dasatinib 2006 Axitinib 2012 Idelalisib 2014 Sunitinib 2006 Bosutinib 2012 Olaparib 2014 Vorinostat 2006 Cabozantinib 2012 Ceritinib 2014 Lapatinib 2007 Ponatinib 2012 Alecitinib
2 Targeted/Biologic Agents (cont) Cobimetinib 2015 Osimertinib 2015 Sonidegib 2015 Ixazomib 2015 Palbociclib 2015 Venetoclax 2016 Lenvatinib 2015 Panobinostat 2015 Cost of Anticancer Medications Dusetzina SB. JAMA Oncol. 2016;2: Cost of Anticancer Medications Increases in monthly drug costs occur Each year following FDA approval Subsequent indication FDA approval Compendia off label indication Introduction of competitor Cost of Anticancer Medications Medical vs pharmacy benefit coverage Infusion and injectables medical plan Orals pharmacy benefit Patient assistance programs Manufacturer rebates/coupons Foundation Formulary/prior authorization Bennette CS. Health Affairs. 2016;35: Access to Oral Anticancer Agents Pause and Ponder What can you do as a community pharmacist to minimize cost and/or access barriers to oral anticancer medications? Schwartz RN, et al. J Natl Compr Canc Netw. 2010;8:S1 S12. 2
3 Administration 62 yo women with breast cancer Palbociclib 125 mg po daily days 1 21 and letrozole 2.5 mg po daily 75 yo man with prostate cancer Abiraterone 1000 mg (4 x 250 mg) po daily and prednisone 5 mg po BID 43 yo man with colon cancer Capecitabine 1000 mg/m 2 po BID and oxaliplatin 130 mg/m 2 IV q 21 days Adherence 46% 100% Nonadherence Side effects Lack of support Forgetfulness Complex regimens/long duration Consequences Disease progression Reduced quality of life Increased healthcare costs Role of the Community Pharmacist Which of the following is the most important thing a community pharmacist can do to facilitate adherence? a. Provide manufacturer s patient information b. Refer patient to cancer care team c. Determine adherence with each refill d. Fill a pill box with medication Interactions Substrates CYP450 P glycoprotein Breast cancer resistance protein (BRCP) Uridine diphosphate glucuronyltransferase (UGT) Acid suppression Warfarin QTc prolongation Warfarin Interactions Increase INR Decrease INR Affects Anticancer Med Capecitabine Darafenib Regorafenib Ceritinib Enzalutamide Dastatinib Erlotinib Flutamide Gefitinib Imatinib Regorafenib Sorafenib Tamoxifen Vemurfenib Vorinostat Interactions Other anticoagulants Certinib and apixaban Dabigatran and lapatinib Idelalisib and apixiban Idelalisib and rivaroxaban Tamoxifen and letrozole Erlotinib and tobacco 3
4 Food Interactions Take With Food Take on Empty Stomach Alecitinib Venetoclax Abiraterone 6 Mercaptopurine Altretamine Vorinostat Afatanib Melphalan Bexarotene Cabozantanib Methotrexate Bosutinib Ceritinib Nilotinib Capecitabine Chlorambucil Pazopanib Cyclophosphamide Dabrafenib Pomalidomide Exemestane Erlotinib Sonidegib Imatinib Estramustine Sorafenib Palbociclib Etoposide Thalidomide Regorafenib Ixazomib Temozolomide Tretinoin Lapatanib Trametinib Trifluridine/Tipiracil Lomustine Chen B, Holle L. Oral cancer therapy. In: Pham T, Holle L. Cancer Therapy: Prescribing Lexi comp, Food Interactions Calcium estamustine, mercaptopurine Grapefruit and other fruit Bexarotene, bosutinib, cyclophosamide, exemestane, imatinib, regorafenib Panobinostat grapefruit, Seville oranges, pomegranate Olaparib grapefruit, Seville oranges Venclexta grapefruit, Seville oranges, starfruit Fat regorafenib Tyramine containing foods procarbazine Lactose Intolerance Take With Food Alecitinib Cobimetinib Dasatinib Nilotinib Palbociclib Ponatinib Sonidegib Patient Case #1 Interactions KS 62 yo BF with metastatic breast cancer cancer now receiving capecitabine 1000 mg/m 2 PO BID days 1 14 and lapatanib 1250 mg po days Which of the following is correct regarding food interactions with these drugs? a. Capecitabine with food, lapatinib without food b. Capecitabine without food, lapatinib with food c. Both with food d. Both without food Patient Case #1 Interactions KS 62 yo BF with metastatic breast cancer cancer now receiving capecitabine 1000 mg/m 2 PO BID days 1 14 and lapatanib 1250 mg po days What potential drug interactions exist with these drugs? Capecitabine Lapatanib Potential Risks Associated with Exposure to Oral Chemotherapy Handling oral chemotherapy agents during storage, preparation, administration and disposal can results in exposure through Inhalation Ingestion Skin contact/absorption Goodin S, et al. J Oncol Pract. 2011;7:
5 What is a Hazardous? Risk is certainly greatest with drugs causing carcinogenicity but other potential hazards Teratogenicity or other developmental toxicity Reproductive toxicity Organ toxicity at low doses Genotoxicity Structure and toxicity profiles mimicking existing hazardous properties Oral Chemotherapy s: Hazardous? Pregnancy category designation National Institute for Occupational Safety & Health (NIOSH) designation Manufacturer handling recommendations ASHP. Am J Health Syst Pharm : Connor T, et al. NIOSH Publication No :1 15 Oral Chemotherapy: Hazardous s? Oral Chemotherapy: Hazardous s? Abiraterone acetate Pregnancy Category NIOSH Manufacturer Handling Recommendations X Yes Based on its mechanism of action, may harm a developing fetus. Therefore, women who are pregnant or women who may be pregnant should not handle without protection (eg, gloves) Pregnancy Category NIOSH Manufacturer Handling Recommendations Dabrafenib D No* None Erlotinib D Yes None Anastrazole D Yes None Capecitabine D Yes Care should be exercised in handling. Tablets should not be cut or crushed. Procedures for proper handling and disposal should be considered. Any unused product should be disposed of in accordance to local requirements. Several guidelines are published. If contact with skin, wash thoroughly, if contact with mucous membranes, flush thoroughly with water Connor T, et al. NIOSH Publication No :1-15; Zytiga [package insert]. Horsham, PA: Janseen Biotech, Inc; May 2014; Xeloda[package insert]. South San Francisco, CA: Genentech USA, Inc; March Imatinib D Yes Is an antineoplastic product. Follow special handling and disposal procedures. Tablets should not be crushed. Direct contact of crushed tablets with the skin or mucous membranes should be avoided. If such contact occurs, wash thoroughly as outlined in the references. Personnel should avoid exposure to crushed tablets. *Not commercially available at time of NIOSH 2014 publication; 2016 draft publication lists it as hazardous. Connor T, et al. NIOSH Publication No :1-15; Gleevac [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Jan Oral Chemotherapy: Hazardous s? Pregnancy NIOSH Manufacturer Handling Recommendations Category Lenalidomide X Yes Care should be exercised when handling drug. Do not open/crush capsules. If powder from capsule comes in contact with skin, wash immediately and thoroughly with soap and water. If contact with mucous membranes, flush with water. Procedures for proper handling and disposal should be considered. Several guidelines published Pazopanib D Yes None Regorafenib D No* Dispose of unused tablets in accordance with local requirements (note must discard unused tablets 7 weeks after opening bottle) Connor T, et al. NIOSH Publication No :1-15; Revlimid [package insert]. Summit, NJ: Celgene Corporation; June 2013; Stivarga [package insert]. Whippany, NJ; Bayer HealthCare Pharmaceuticals Inc; At the Community Pharmacy Handling Use current packaging Avoid automatic counting devices Wear personal protective equipment Cutting/crushing/manipulating or administering these tablets/capsules Compounding or administration of oral liquids Storage Separate storage Provide in plastic bag for transport Labeling Clear instructions Hazardous drug label 5
6 Handling Oral Hazardous s (cont) Patients handling Wash hands after administration Use separate pill boxes Swallow medication whole Wash hands after using toilet or if vomiting Caregiver handling Pregnant, breastfeeding or children should not handle drug or waste Wash hands and wear gloves when administering Avoid contact with waste Goodin S, et al. J Oncol Pract. 2011;7:7-12. Hazardous Disposal Incorrect disposal of hazardous drugs Can pollute water and ground Be toxic to plants, animals, humans Dispensed oral chemotherapy is Considered household wastes not institutional waste Managed by local and state environmental agencies, like CT Department of Energy and Environmental Protection and Control Environmental Protection Agency. Available at: Accessed January 21, Oral Chemotherapy: Proper Disposal Guidance The 2013 Updated American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) Chemotherapy Administration Standards Stress the importance of patient/caregiver education on proper disposal BUT Provide no specifics on proper disposal process 2011 Safe Handling of Oral Chemotherapy International Pharmacy Panel recommend Return wet, damaged, unused, discontinued, or expired drugs to pharmacist or hospital for disposal Neuss MN, et al. J Oncol Pract. 2013;9:5S-13S; Goodin S, et al. J Oncol Pract. 2011;7:7-12. Oral Chemotherapy: Proper Disposal Guidance ASCO s Cancer.Net (a reputable patient education resource) recommends patients Talk with the doctor or pharmacist or read the information the comes with drug about how to properly dispose Never flush oral chemotherapy or put in the trash Return any unused oral chemotherapy to doctor/nurse for disposal Ask healthcare team ahead of time if empty containers or other chemotherapy waste needs to be returned to office or treatment center for disposal Safe storage and disposal of cancer medications. Available at: Accessed January 21, UConn Health: Oral Chemotherapy Disposal Program CT Department of Energy & Environmental Protection and Division of Control who approved disposal program Allows Neag Cancer Center patients receiving oral chemotherapies to dispose of them at UConn Health Other medications, opioids, prescription drugs, over the counter drugs or supplements are not allowed to be disposed in this program UConn Health: Oral Chemotherapy Disposal Disposal Train Personnel Collection Patient Education 6
7 Knowledge Check Questions? You are preparing a capecitabine prescription for dispensing. Which of the following handling instructions is correct? a. Wash hands and use a separate counting tray b. Wash hands, don gloves, and use a separate counting tray c. Wash hands, don gloves, and use an automatic counting machine d. Wash hands and use automatic counting machine 7
MEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationOverview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)
Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationThe role of the community pharmacy team in assisting patients receiving oral anticancer medications
AND AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS 2 CPE CredITs EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM/CPE EDUCATIONAL OBJECTIVES GOAL: To educate
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationAdditional information to support. The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines
Additional information to support The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines Reference: NPSA/2008/RRR001 - issued on 22 January 2008
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationSafe handling of oral anticancer agents
What do we mean by safe handling? Safe handling of oral anticancer agents Jude Lees Senior Pharmacist Royal Adelaide Hospital Cancer Centre Adelaide, South Australia Exposure with IV chemo Many Oral Agents
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior
More informationSafe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre
Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre ABSTRACT Sim M.H. 1, Leow Y.C. 2 and Chan A. 3 Department of Pharmacy, Faculty of Science, National
More informationPharmacy Medical Necessity Guidelines: Oral Cancer Medications
Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name abiraterone acetate (A-bih-RA-the-rone A-seh-tayt) Brand name Zytiga (zye-tee-ga) Approved uses Abiraterone acetate is used in combination with prednisone to treat
More informationOral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature
Focus on Quality Original Contribution Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature By Eve M. Segal, PharmD, Megan R. Flood, PharmD, Robert S. Mancini, PharmD,
More informationSafe Handling of Oral Anti Cancer Therapy Don t Ask Don t Touch. Disclosure. Objectives 3/9/2012. Speaker s Bureau/Governing Board: Celgene, Merck
Safe Handling of Oral Anti Cancer Therapy Don t Ask Don t Touch Sandra Cuellar, PharmD, BCOP Clinical Assistant Professor Clinical Oncology Pharmacist University of Illinois at Chicago College of Pharmacy
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationFrom the Clinic to Home: The Shift to Oral Oncolytic Therapy
From the Clinic to Home: The Shift to Oral Oncolytic Therapy Eric Vachon, BSN, RN Michigan State University, College of Nursing Disclosure I do not have anything to disclose. Objectives Oral oncolytics
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name letrozole (LEH-truh-zole) Brand name Femara (FEH-muh-ruh) Approved uses Letrozole is used in the treatment of certain types of hormone-dependent breast cancer in postmenopausal
More informationSorafenib (Nexavar ) ( sor-af-e-nib )
Sorafenib (Nexavar ) ( sor-af-e-nib ) How the drug is given: by mouth Purpose: To stop the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth Take on
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name tamoxifen citrate (tuh-mok-sih-fen SIH-trayt) Brand name Soltamox (SOL-ta-mox) Approved uses Tamoxifen is used to treat certain types of hormone-dependent breast cancer
More informationUSP 800 and Hazardous Medications
USP 800 and Hazardous Medications Trung H. Nguyen, PharmD and Alesha Davis, CPhT Dayton VA Medical Center Trung.Nguyen610@va.gov Alesha.Davis@va.gov The speaker has no actual or potential conflict of interest
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationImatinib (Gleevec ) ( eye-mat-eh-nib )
Imatinib (Gleevec ) ( eye-mat-eh-nib ) How drug is given: by mouth Purpose: stops growth of cancer cells in leukemia, gastrointestinal stromal tumors (GIST), and other cancers How to take the drug by mouth
More informationMETHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF
Mary Pack Arthritis Program METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Handling of premixed injectable Methotrexate (MTX) by employees who are pregnant, breast-feeding or attempting to reproduce
More informationEverolimus (Afinitor )
Everolimus (Afinitor ) ( e-ver-oh-li-mus ) How drug is given: By mouth Purpose: to slow the growth of cancer cells in kidney cancer and other cancers How to take the drug Take with or without food and
More informationOral Systemic Therapy
Oral Systemic Therapy This information does not take the place of the care and advice of your Cancer Care Team. Talk to your Cancer Care Team about your health concerns, treatment options and any questions
More informationDabrafenib (Tafinlar )
Dabrafenib (Tafinlar ) ( da-braf-e-nib ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in melanoma and other cancers. How to take this drug Take this medication on an empty stomach
More informationOral Chemotherapy Program at THP. Dr. Katherine Enright MD, MPH, FRCPC
Oral Chemotherapy Program at THP Dr. Katherine Enright MD, MPH, FRCPC What is Oral Chemotherapy? Oral Chemotherapy is Classic Chemotherapy Drugs: Capecitabine (Xeloda) Hydroxyurea (Hydrea) Melphalan Chlorambucil
More informationHazardous Medication List
Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationIbrutinib (Imbruvica )
Ibrutinib (Imbruvica ) ( eye BROO ti nib ) How drug is given: by mouth Purpose: to stop the growth of cancer cells in lymphoma and other cancers How to take the drug Take each dose at the same time every
More informationSAFE PRACTICES IN ORAL CHEMOTHERAPY:
SAFE PRACTICES IN The Pharmacist s Role in the Outpatient Management of Oral Chemotherapy-Induced and Prevention of Drug Interactions DISCLOSURES I have no conflicts of interest to disclose related to
More informationThe Un-Special World of Specialty Medications
The Un-Special World of Specialty Medications Manpreet Chahal, PharmD, PhD Oncology Pharmacist, Medical Oncology Associates, Spokane WA Adjunct Clinical Instructor, WSU College of Pharmacy mschahal@wsu.edu
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationOral Systemic Therapy
Patient & Family Guide 2018 Oral Systemic Therapy www.nscancercare.ca Patient s Name: Type of Treatment: Cancer Doctor: Cancer Clinic: Phone Number: Emergency Department Phone Number: Who do I call if
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication TER Generic name venetoclax (veh-neh-toh-klax) Brand name Venclexta (ven-klek-stuh) Approved uses Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
More informationCardio-Oncology: Past Present and Future
Cardio-Oncology: Past Present and Future Lakkana Suwannoi PharmD BCPS BCOP Division of Clinical Pharmacy Faculty of Pharmacy Mahidol University Bangkok THAILAND Outline I. Cardiovascular disease & cancer
More informationBritish Columbia Cancer Agency
Page 1 of 12 A. SCOPE This Policy covers the preparation, administration, and disposal of hazardous drugs. See Cancer Drug Manual Appendix 5 for the Hazardous Drug List. (www.bccancer.bc.ca/hpi/drugdatabase/appendices)
More informationASCO s Quality Training Program
ASCO s Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacistmanaged oral chemotherapy follow-up program Presenter s Name: Sonja Jacobsen,
More informationEltrombopag (Promacta )
Eltrombopag (Promacta ) ( el TROM boe pag ) How drug is given: By mouth Purpose: to treat aplastic anemia and increase low platelet counts in some conditions How to take this drug 1. Take this medication
More informationOral Chemotherapy Panel
Panel Disclosures Dr. Chen & Dr. Hudson-DiSalle no relevant financial relationships exist with commercial interests Oral Chemotherapy Panel Dr. Mancini - Speaker s Bureau for Millennium Pharmaceuticals
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name Ruxolitinib (RUK-soh-LI-ti-nib) Brand name Jakafi (JA-kah-fy) Approved uses Ruxolitinib is used to treat patients with myelofibrosis and polycythemia vera. Dose and
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More information10/5/2017. Role of the Pharmacist in Adverse Event Management and Prevention With Oral Targeted Anticancer Agents. Faculty and Staff Disclosures
Role of the Pharmacist in Adverse Event Management and Prevention With Oral Targeted Anticancer Agents Role of the Pharmacist in Adverse Event Management and Prevention With Oral Targeted Anticancer Agents
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationIBRANCE (palbociclib) oral capsule
IBRANCE (palbociclib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name vismodegib (VIS-moh-DEH-gib) Brand name Erivedge (AYR-ih-vej) Approved uses Vismodegib is used to treat advanced or metastatic basal cell carcinoma. Dose and schedule
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name lapatinib (luh-pa-tih-nib) Brand name Tykerb (TY-kerb) Approved uses Lapatinib is used in combination to treat advanced or metastatic breast cancer that overexpresses
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name thioguanine (THY-oh-GWAH-neen) Brand name Tabloid (TAB-loyd) Approved uses Thioguanine is used to treat adult and pediatric patients with acute myeloid leukemia (AML).
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationMidostaurin (Rydapt )
Midostaurin (Rydapt ) ( mye doe STAW rin ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in acute myeloid leukemia (AML) and other cancers. How to take this drug 1. Take this
More informationOral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy
Oral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy 1 Objectives Identify the more commonly dispensed oral chemotherapy drugs and their indications/dosage
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name ixazomib (ik-sa-zoh-mib) Brand name Ninlaro (nin-lar-oh) Approved uses Ixazomib is used to treat multiple myeloma (MM) in combination with lenalidomide and dexamethasone.
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationTake the Lead: Pharmacists Growing Role in Managing Oral Oncologics Ashley Glode, Pharm.D., BCOP Megan May, Pharm.D., BCOP
Take the Lead: Pharmacists Growing Role in Managing Oral Oncologics Ashley Glode, Pharm.D., BCOP Megan May, Pharm.D., BCOP Target Audience: Pharmacists ACPE#: 0202-0000-18-057-L01-P Activity Type: Application-based
More informationLenvatinib (Lenvima ) ( len-va-ti-nib )
Lenvatinib (Lenvima ) ( len-va-ti-nib ) How drug is given: By mouth Purpose: To treat thyroid cancer or other cancers How to take this drug This medicine can be taken with or without food. Take each dose
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name procarbazine (proh-kar-buh-zeen) Brand name Matulane (MA-choo-layn) Approved uses Procarbazine is used to treat Hodgkin s disease. Dose and schedule Taking procarbazine
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name brigatinib (brih-ga-tih-nib) Brand name Alunbrig (uh-lun-brig) Approved uses Brigatinib is used to treat metastatic non-small cell lung cancer (NSCLC) that has a genetic
More informationPanel Discussion: Orals Adherence & Challenges Friday, April 28 th, 2017
Panel Discussion: Orals Adherence & Challenges Friday, April 28 th, 2017 1 2017 Community Oncology Alliance Panel Discussion: Orals Adherence & Challenges Ray Bailey, RPh, Director of Pharmacy Florida
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationMedication burden of treatment using oral cancer medications
Medication burden of treatment using oral cancer medications Item Type Article Authors Given, BarbaraA; Given, CharlesW; Sikorskii, Alla; Vachon, Eric; Banik, Asish Citation Medication burden of treatment
More informationExposure Control Plan for Cytotoxic Substances
Exposure Control Plan Department of www.rms.ubc.ca UBC-RMS-OHS-ECP-17-001 Effective date: December 8, 2017 Review date: NA Supersedes: NA 1. PURPOSE Exposure Control Plan for Cytotoxic Substances The University
More informationMonoclonal Antibodies & Tyrosine-Kinase Inhibitors
Monoclonal Antibodies & Tyrosine-Kinase Inhibitors Charlotte Capstick Clinical Pharmacist Oncology Weston Park Hospital Sheffield Teaching Hospitals NHS Trust Contents Background Dosing Renal impairment
More informationOpen to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level
If you have multiple myeloma and have already tried at least 2 other types of treatment Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level What is
More informationDrugs with Handling Concerns Due to Reproductive Risk
PL Detail-Document #280513 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2012 Drugs with Handling
More informationTreatment Journal. Therapy Tracker TREATMENT JOURNAL
TREATMENT JOURNAL Treatment Journal & Therapy Tracker Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for FARYDAK (panobinostat) capsules. This journal can help you:
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationHazardous Drug Safety
Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions: To receive credit for completion: 1. Read the content
More informationORAL CHEMOTHERAPY EDUCATION
Name of your medication Generic name dabrafenib (duh-bra-feh-nib) Brand name Tafinlar (TA-fin-lar) Approved uses Dabrafenib is used to treat patients with: o Melanoma that has a genetic mutation called
More informationAn oncology reviewer s perspective on hepatotoxicity
An oncology reviewer s perspective on hepatotoxicity Gideon Blumenthal, MD March 21 2013 FDA/Critical Path DILI conference Disclaimer: Views expressed herein are my own and may not necessarily reflect
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationTable 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents* Cardiac Drug(s) Enzyme/ Action Chemotherapy Drug Effect of Drug- Drug Interaction Suggested Oncologist Management Suggested
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationReview Article Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 309601, 7 pages http://dx.doi.org/10.1155/2015/309601 Review Article Prevention of Nausea and Vomiting in Patients Undergoing
More information